Rayence Co

Rayence Co LT Debt/Equity

The Long-Term Debt to Equity Ratio of Rayence Co (228850.KQ) as of Nov 7, 2026 is 0.01.

LT Debt/Equity

0.01

YoY

120.92%

Last updated:

Long-Term Debt to Equity Ratio of Rayence Co is 2024 0.01 . Long-Term Debt to Equity Ratio of Rayence Co was 2023 0.00 . It decreases by 120.92% higher compared to the previous year.

The Rayence Co LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2017
0.00 KRW
Jan 1, 2018
0.00 KRW
Jan 1, 2019
0.00 KRW
Jan 1, 2020
0.01 KRW
Jan 1, 2021
0.00 KRW
Jan 1, 2022
0.00 KRW
Jan 1, 2023
0.00 KRW
Jan 1, 2024
0.01 KRW
The Rayence Co LT Debt/Equity history
YEARLT Debt/EquityYoY
0.01+120.92%
0.00+171.31%
0.00-45.30%
0.00-47.69%
0.01+48.61%
0.00—
0.00-100.00%
0.00-78.75%
0.01-83.21%
0.07-49.66%
0.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

Long-Term Debt to Equity Ratio of Rayence Co is 0.01 in 2024.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Rayence Co since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Rayence Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Rayence Co

All Key Metrics — Rayence Co